ZEST niraparib versus placebo in ctDNA-positive early breast cancer

Phase 3, randomised, double-blind trial of niraparib in breast cancer and triple-negative breast cancer (TNBC) (4 cohorts), sponsored by Takeda. Primary endpoints: Number of participants with treatment-emergent adverse events, serious adverse events, and adverse events of special interest, Number of participants with TEAEs leading to death and 6 more. Started Jun 2021; status: active, not recruiting.